Regulatory authorities are increasingly recommending adjudication of safety and efficacy events, such as interstitial lung disease (ILD), in clinical trials. To meet this requirement, trial sponsors turn to independent clinical event committees (CECs) as the most efficient way to help reduce costs, increase quality, and eliminate clinical bias.

In this webinar, we will discuss:

• Event adjudication objectives and the role and value of the CEC as an unbiased entity in the drug development process
• Unexpected observations that enabled the sponsor to design new studies, modify data collection, and create education and training programs to identify and treat ILD
• Critical components of the adjudication program that gave the committee members the platform to perform an accurate and timely review of findings